Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/23209
Title: | Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome |
Authors: | YAMAKAMI, L. Y. S.; ARAUJO, D. B. de; SILVA, C. A.; BARACAT, E. C.; CARVALHO, J. F. de |
Citation: | LUPUS, v.20, n.5, p.523-526, 2011 |
Abstract: | Antiphospholipid syndrome (APS) is a disorder of coagulation that causes thrombosis as well as pregnancy-related complications, occurring due to the autoimmune production of antibodies against phospholipid. Full anticoagulation is the cornerstone therapy in patients with thrombosis history, and this can lead to major bleeding. During a 3-year period, 300 primary and secondary APS patients were followed up at the Rheumatology Division of the authors' University Hospital. Of them, 255 (85%) were women and 180 (60%) were of reproductive age. Three of them (1%) had severe hemorrhagic corpus luteum while receiving long-term anticoagulation treatment and are described in this report. All of them were taking warfarin, had elevated international normalized ratio (> 4.0) and required prompt blood transfusion and emergency surgery. Therefore, we strongly recommend that all women with APS under anticoagulation should have ovulation suppressed with either intramuscular depot-medroxyprogesterone acetate or oral desogestrel. Lupus (2011) 20, 523-526. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MOG Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/ICr Artigos e Materiais de Revistas Científicas - LIM/36 Artigos e Materiais de Revistas Científicas - LIM/58 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_YAMAKAMI_Severe_hemorrhagic_corpus_luteum_complicating_anticoagulation_in_antiphospholipid_2011.PDF Restricted Access | publishedVersion (English) | 72.32 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.